MAPT and Alzheimer disease: Accuracy increases when both CSF biomarkers are combined, as shown by a study with neuropathological confirmation of the diagnosis, which showed that the p-tau/Aβ42 ratio has a sensitivity of 91.6% and a specificity of 85.7% for AD diagnosis [32].